Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 3
1947 2
1950 1
1951 4
1953 3
1954 5
1955 6
1956 10
1957 9
1958 8
1959 6
1960 13
1961 21
1962 27
1963 38
1964 101
1965 50
1966 57
1967 59
1968 76
1969 85
1970 72
1971 94
1972 69
1973 102
1974 106
1975 120
1976 106
1977 126
1978 125
1979 132
1980 116
1981 107
1982 156
1983 157
1984 177
1985 187
1986 190
1987 189
1988 168
1989 230
1990 195
1991 203
1992 206
1993 169
1994 216
1995 217
1996 233
1997 221
1998 219
1999 214
2000 262
2001 207
2002 236
2003 252
2004 258
2005 265
2006 310
2007 298
2008 305
2009 310
2010 324
2011 317
2012 378
2013 349
2014 393
2015 346
2016 383
2017 321
2018 299
2019 324
2020 193
Text availability
Article attribute
Article type
Publication date

Search Results

10,959 results
Results by year
Filters applied: . Clear all
Page 1
Pharmacokinetics of Melphalan After Intravitreal Injection in a Rabbit Model.
Buitrago E, Winter U, Williams G, Asprea M, Chantada G, Schaiquevich P. Buitrago E, et al. J Ocul Pharmacol Ther. 2016 May;32(4):230-5. doi: 10.1089/jop.2015.0088. Epub 2016 Jan 19. J Ocul Pharmacol Ther. 2016. PMID: 26785130
Therefore, in this study, we characterized the ocular and systemic disposition of melphalan after intravitreal injection in the rabbit eye. ...CONCLUSION: Intravitreal administration of 15 μg melphalan leads to pharmacological vitreous levels with low aqueous exposu …
Therefore, in this study, we characterized the ocular and systemic disposition of melphalan after intravitreal injection in the rabbi …
Oral melphalan for the treatment of relapsed canine lymphoma.
Mastromauro ML, Suter SE, Hauck ML, Hess PR. Mastromauro ML, et al. Vet Comp Oncol. 2018 Mar;16(1):E123-E129. doi: 10.1111/vco.12356. Epub 2017 Sep 21. Vet Comp Oncol. 2018. PMID: 28941072
Retrospective evaluation of 19 cases of relapsed canine lymphoma treated with oral melphalan was performed. Melphalan was primarily administered (n = 16) via a high dose protocol (HDM) with a median dosage of 19.4 mg m(-2) . ...Times to progression following melp
Retrospective evaluation of 19 cases of relapsed canine lymphoma treated with oral melphalan was performed. Melphalan was prim …
High-dose melphalan and stem cell transplantation in systemic AL amyloidosis in the era of novel anti-plasma cell therapy: a comprehensive review.
Varga C, Comenzo RL. Varga C, et al. Bone Marrow Transplant. 2019 Apr;54(4):508-518. doi: 10.1038/s41409-018-0284-4. Epub 2018 Aug 8. Bone Marrow Transplant. 2019. PMID: 30089901 Review.
The application of high-dose melphalan and autologous stem cell transplant (SCT) to systemic AL amyloidosis (AL) has evolved over the past two decades and remains an important component of therapy for patients with AL. ...In this review, we touch on the history of SCT for …
The application of high-dose melphalan and autologous stem cell transplant (SCT) to systemic AL amyloidosis (AL) has evolved over the …
Safety and efficacy of propylene glycol-free melphalan as conditioning in patients with AL amyloidosis undergoing stem cell transplantation.
Sidiqi MH, Aljama MA, Muchtar E, Buadi FK, Warsame R, Lacy MQ, Dispenzieri A, Dingli D, Leung N, Gonsalves WI, Kapoor P, Kourelis TV, Hogan WJ, Wolf RC, Kumar SK, Gertz MA. Sidiqi MH, et al. Bone Marrow Transplant. 2019 Jul;54(7):1077-1081. doi: 10.1038/s41409-018-0388-x. Epub 2018 Nov 2. Bone Marrow Transplant. 2019. PMID: 30390060
Median time to neutrophil and platelet engraftment was the same; 14 days PG melphalan vs 14 days PG-free melphalan, p = 0.73 and 16 days PG melphalan vs 16 days PG-free melphalan, p = 0.52, respectively. ...Overall response rate (ORR) and rates of comp …
Median time to neutrophil and platelet engraftment was the same; 14 days PG melphalan vs 14 days PG-free melphalan, p = 0.73 a …
Melphalan 140 mg/m(2) or 200 mg/m(2) for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party.
Auner HW, Iacobelli S, Sbianchi G, Knol-Bout C, Blaise D, Russell NH, Apperley JF, Pohlreich D, Browne PV, Kobbe G, Isaksson C, Lenhoff S, Scheid C, Touzeau C, Jantunen E, Anagnostopoulos A, Yakoub-Agha I, Tanase A, Schaap N, Wiktor-Jedrzejczak W, Krejci M, Schönland SO, Morris C, Garderet L, Kröger N. Auner HW, et al. Haematologica. 2018 Mar;103(3):514-521. doi: 10.3324/haematol.2017.181339. Epub 2017 Dec 7. Haematologica. 2018. PMID: 29217776 Free PMC article. Clinical Trial.
There were no significant survival or relapse rate differences between melphalan 200 mg/m(2) and melphalan 140 mg/m(2) patients with high-risk or standard-risk chromosomal abnormalities. In conclusion, remission status at the time of transplantation may favor the us …
There were no significant survival or relapse rate differences between melphalan 200 mg/m(2) and melphalan 140 mg/m(2) patient …
High dose melphalan and autologous peripheral blood stem cell transplantation in AL amyloidosis.
Sanchorawala V. Sanchorawala V. Hematol Oncol Clin North Am. 2014 Dec;28(6):1131-44. doi: 10.1016/j.hoc.2014.08.013. Epub 2014 Sep 30. Hematol Oncol Clin North Am. 2014. PMID: 25459183 Review.
This article outlines the role of high-dose melphalan and stem cell transplantation. This year marks the 20th anniversary for the first patient who underwent successful stem cell transplantation for this disease at Boston Medical Center....
This article outlines the role of high-dose melphalan and stem cell transplantation. This year marks the 20th anniversary for the fir …
Stability of Melphalan in 0.9% Sodium Chloride Solutions Prepared in Polyvinyl Chloride Bags for Intravenous Injection.
Desmaris RP, Mercier L, Paci A. Desmaris RP, et al. Drugs R D. 2015 Sep;15(3):253-9. doi: 10.1007/s40268-015-0098-4. Drugs R D. 2015. PMID: 26178037 Free PMC article.
According to the manufacturer, melphalan is stable in sterile 0.9% sodium chloride for 90 min at room temperature (RT). Several authors have studied the stability of different concentrations of melphalan; however, most were not adapted to the current manufacturing p …
According to the manufacturer, melphalan is stable in sterile 0.9% sodium chloride for 90 min at room temperature (RT). Several autho …
The systemic administration of intravenous melphalan.
Sarosy G, Leyland-Jones B, Soochan P, Cheson BD. Sarosy G, et al. J Clin Oncol. 1988 Nov;6(11):1768-82. doi: 10.1200/JCO.1988.6.11.1768. J Clin Oncol. 1988. PMID: 3054005 Review.
In addition, unlike oral melphalan, an extensive phase I evaluation of IV melphalan has not been undertaken. At lower doses (eg, 30 to 70 mg/m2), both as a single agent and in combination, the activity of IV melphalan has been evaluated in only a limited numb …
In addition, unlike oral melphalan, an extensive phase I evaluation of IV melphalan has not been undertaken. At lower doses (e …
Melphalan.
Rep Carcinog. 2004;11:III164. Rep Carcinog. 2004. PMID: 21089900 No abstract available.
Pharmacokinetic-Pharmacodynamic Model of Neutropenia in Patients With Myeloma Receiving High-Dose Melphalan for Autologous Stem Cell Transplant.
Cho YK, Irby DJ, Li J, Sborov DW, Mould DR, Badawi M, Dauki A, Lamprecht M, Rosko AE, Fernandez S, Hade EM, Hofmeister CC, Poi M, Phelps MA. Cho YK, et al. CPT Pharmacometrics Syst Pharmacol. 2018 Nov;7(11):748-758. doi: 10.1002/psp4.12345. Epub 2018 Oct 20. CPT Pharmacometrics Syst Pharmacol. 2018. PMID: 30343510 Free PMC article.
High-dose melphalan (HDM) is part of the conditioning regimen in patients with multiple myeloma (MM) receiving autologous stem cell transplantation (ASCT). ...Granulocyte-colony stimulating factor (G-CSF) is given to stimulate neutrophil proliferation after melphalan
High-dose melphalan (HDM) is part of the conditioning regimen in patients with multiple myeloma (MM) receiving autologous stem cell t …
10,959 results
Jump to page
Feedback